Pasithea Therapeutics Corp. (KTTAW) Research & Development (2022 - 2026)

Pasithea Therapeutics has disclosed Research & Development across 5 years of filings, most recently posting $3.7 million for Q2 2026.

• In Q2 2026, Research & Development rose 71.53% year-over-year to $3.7 million; the TTM figure through Jun 2026 stood at $10.7 million (up 53.95% YoY), while the FY2025 annual figure was $8.0 million, up 10.87% from the prior year.
• Research & Development came in at $3.7 million for Q2 2026 at Pasithea Therapeutics, up from $2.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $3.7 million in Q2 2026 to a low of $1.1 million in Q1 2023.
• Average Research & Development over 5 years is $2.0 million, with a median of $1.7 million recorded in 2024.
• Year-over-year, Research & Development soared 141.73% in 2023 and tumbled 54.95% in 2024.
• Over 5 years, Research & Development stood at $1.4 million in 2022, then soared by 141.73% to $3.4 million in 2023, then plunged by 54.95% to $1.5 million in 2024, then jumped by 81.77% to $2.7 million in 2025, then surged by 34.28% to $3.7 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $3.7 million in Q2 2026, $2.9 million in Q1 2026, and $2.7 million in Q4 2025.